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Background-—There is growing evidence that sleep duration and quality may be associated with cardiovascular harm and mortality.
Methods and Results-—We conducted a systematic review, meta-analysis, and spline analysis of prospective cohort studies that
evaluate the association between sleep duration and quality and cardiovascular outcomes. We searched MEDLINE and EMBASE for
these studies and extracted data from identiﬁed studies. We utilized linear and nonlinear dose-response meta-analysis models and
used DerSimonian–Laird random-effects meta-analysis models of risk ratios, with inverse variance weighting, and the I2 statistic to
quantify heterogeneity. Seventy-four studies including 3 340 684 participants with 242 240 deaths among 2 564 029 participants
who reported death events were reviewed. Findings were broadly similar across both linear and nonlinear dose-response models in
30 studies with >1 000 000 participants, and we report results from the linear model. Self-reported duration of sleep >8 hours
was associated with a moderate increased risk of all-cause mortality, with risk ratio, 1.14 (1.05–1.25) for 9 hours, risk ratio, 1.30
(1.19–1.42) for 10 hours, and risk ratio, 1.47 (1.33–1.64) for 11 hours. No signiﬁcant difference was identiﬁed for periods of self-
reported sleep <7 hours, whereas similar patterns were observed for stroke and cardiovascular disease mortality. Subjective poor
sleep quality was associated with coronary heart disease (risk ratio, 1.44; 95% conﬁdence interval, 1.09–1.90), but no difference in
mortality and other outcomes.
Conclusions-—Divergence from the recommended 7 to 8 hours of sleep is associated with a higher risk of mortality and
cardiovascular events. Longer duration of sleep may be more associated with adverse outcomes compared with shorter sleep
durations. ( J Am Heart Assoc. 2018;7:e008552. DOI: 10.1161/JAHA.118.008552.)
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C ardiovascular disease (CVD) causes over 787 000deaths in the United States.1 Whereas sleep duration
is generally not considered a traditional risk factor for cardio-
vascular disease (CVD), growing evidence supports its associ-
ation with cardiovascular risk (CVR) factors2–7 and disease,8–11
and quality of sleep appears to contribute to CVR.10,12 Yet,
current guidelines for the risk reduction of CVD make limited
recommendations about quality or duration of sleep.13,14
The National Sleep Foundation recommends 7 to
9 hours of sleep for people aged 26 to 64 years and 7
to 8 hours of sleep for people aged ≥65 years,14 and the
Centers for Disease Control and Prevention has similar
recommendations for adults.15 Whether adults sleep the
recommended hours is inﬂuenced by cultural, social,
psychological, behavioral, pathophysiological, and environ-
mental inﬂuences.16,17 Sleep duration may be reduced
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because of irregular working and shift-work patterns and
round-the-clock availability of commodities of modern
society.18 However, guidelines make no speciﬁc reference
with regard to sleeping beyond the recommended limit.
Long sleep duration may be associated with obstructive
sleep apnea, heart disease, and failing health19 or may
represent a symptom of early “latent” disease preceding a
formal diagnosis.20
Although previous reviews have evaluated sleep duration
and mortality and cardiovascular outcomes,10,16 these
reviews have not quantiﬁed the CVR associated with each
hour deviation below or above the recommended sleep
duration. In addition, none of the previous reviews assessed
the inﬂuence of sleep quality.10,16 Thus, we conducted a
systematic review and meta-analysis of the impact of sleep
duration and quality on CVD and mortality.
Methods
Data, analytical methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
The full methods, including detailed eligibility criteria,
search strategy, data selection, extraction, and analysis,
are reported in Data S1. The article was prepared
according the guidance of the Meta-analysis of Obser-
vational Studies in Epidemiology (MOOSE) statement
(Data S2).
Eligibility Criteria
We selected prospective cohort studies that reported on
participants who quantiﬁed their duration of sleep or quality of
sleep, and their association with subsequent CVD and
mortality. The primary outcome was all-cause mortality, and
secondary outcomes were CVD and mortality.
Search Strategy
WesearchedMedline and Embase usingOvidSP (from inception
to the end of October 2015) using the search terms in Data S3.
Study Selection and Data Extraction
Two reviewers (C.S.K. and A.M.) checked all titles and
abstracts for studies that could potentially meet the inclusion
criteria. Data extraction and risk of bias assessment were
performed independently by at least 2 reviewers (C.S.K., G.K.,
or M.G.). Publication bias was assessed using funnel plots.
Statistical Analysis
We used Stata software (version 14; StataCorpLP, College
Station, TX) to perform regression analysis with random-
effects dose-response meta-analysis models to estimate the
association between hours of sleep and adverse outcomes,
using 7 hours of sleep as the reference category. The linear
model represents the primary analysis, and the cubic model
was included as a supplemental analysis.
Conventional random-effects meta-analysis was performed
as a secondary analysis using RevMan 5.3 (The Nordic
Cochrane Centre, The Cochrane Collaboration, Copenhagen,
Denmark). We decided to use random-effects models because
they are more conservative compared with ﬁxed-effect
models, in the presence of any heterogeneity. Statistical
heterogeneity was assessed using the I2 statistic. The details
of the main and sensitivity analyses are described in Data S1.
We also performed analysis of sleep quality (Data S4) in
relation to mortality and cardiovascular outcomes.
Results
Description of Included Studies
A total of 74 studies met the inclusion criteria; the process of
study selection is shown in Figure 1.8,9,11,12,21–90 Study
design and participant characteristics are shown in Table 1.
The included studies were dated 1970–2017, which repre-
sented 3 340 684 participants. Among studies that reported
crude events, there were 242 240 all-cause deaths in
2 564 029 participants from 44 studies (9.4%), 5435 coro-
nary heart disease (CHD) deaths in 741 695 participants from
Clinical Perspective
What Is New?
• In this meta-analysis of 74 studies representing over
3 million participants, we found a J-shaped relationship
between sleep duration and mortality and incident cardio-
vascular disease.
• Duration of sleep >8 hours of sleep was associated with
increased risk of mortality.
• No signiﬁcant effect was identiﬁed for periods of sleep
<7 hours. Similar patterns were observed for stroke and
cardiovascular disease mortality.
• Subjective poor sleep quality was associated with a
signiﬁcant increase in coronary heart disease, but not other
outcomes.
What Are the Clinical Implications?
• Our study suggests that abnormal sleep is a marker of
elevated cardiovascular risk.
• Future work should evaluate whether attention to optimizing
the duration and quality of sleep may help reduce the
burden of cardiovascular disease.
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7 studies (0.7%), 6380 stroke deaths in 374 728 participants
from 5 studies (1.7%), 32 988 cardiovascular deaths in
759 939 participants from 14 studies (4.3%), 32 084 CHD
events in 540 538 participants from 14 studies (5.9%),
14 946 stroke events in 525 620 participants from 11
studies (2.8%), and 4160 CVD events in 97 832 participants
from 6 studies (4.3%). Data S5 shows the prevalence of CVD
and CVR factor proﬁles for each cohort.
Quality Assessment of Included Studies
The quality assessment is shown in Data S6. Studies used
questionnaires or direct questioning to ascertain information
about sleep quality or sleep duration. Methods used to
estimate outcomes included population registries, death
certiﬁcation, questionnaires, and review of medical records
or patient through interview or telephone call. Most studies
adjusted for potential confounders, but the factors adjusted
for varied across studies. Loss to follow-up was unclear in 30
studies, and 12 studies had 10% or more loss to follow-up or
missing data. The study reference group and studies included
for each analysis are shown in Data S7.
Sleep Duration and All-Cause Mortality
Numeric results of analyses are shown in Tables 2 and 3. For the
spline analysis, a total of 30 studies* reported data that could be
used for the all-causemortality analysis.When spline analysiswas
applied using a linear model, incremental deviation <7 hours of
self-reported sleep was not associated with increased risk of all-
cause mortality, but sleep durations >8 hours were associated
with increased risk of all-cause mortality (Figure 2). The cubic
spline analysis model is shown in Data S8.
Pooled risk of all-cause mortality for the entire cohort
(Figure 2, Data S9) and the subgroup of men and women only
are shown in Data S10. There were a total of 39 studies
included in the analysis.** The funnel plot for sleep duration
and mortality did not suggest that there was publication bias.
Deviation from self-reported sleep duration of 7 or 8 hours
appeared to be associated with all-cause mortality, where
Figure 1. Flow diagram of study inclusion.
*References 11, 21, 23, 25, 26, 29, 32, 33, 36, 41, 44, 47–49, 52, 55–57, 60,
64, 66, 68, 70, 71, 79, 80, 84, 86–88.
**References 11, 21, 23, 25–27, 29, 32–34, 36, 39–41, 44, 46–49, 51–54,
56, 57, 61, 64, 66, 68, 70–72, 77, 79, 80, 84, 86–88.
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Table 1. Study Design and Demographics Table
Study ID Design; Country; Year
No. of
Participants
Mean
Age, y % Male Participant Inclusion Criteria
Akersted, 201721 Prospective cohort study;
Sweden; 1997–2010
43 868 51 36 Participants were aged >18 y in the Swedish
National March study.
Amagai, 201022 Prospective cohort study;
Japan; April 1992 to July
1995
11 367 55 39 Participants were adults of varying ages in 12 rural
areas of Japan from the Jichi Medical School
Cohort Study.
Aurora, 201623 Prospective cohort study;
USA; 1995–2011
5784 64 46 Participants were aged 40 y and not treated for
sleep-disordered breathing in the Sleep Heart
Health Study.
Ayas, 200324 Prospective cohort study;
USA; 1986–1996
71 617 Unclear 0 Participants were US female health professionals
aged 45 to 65 y who were enrolled in the
Nurses’ Health Study.
Bellavia, 201425 Prospective cohort study;
Sweden; 1998–2012
70 973 Unclear 53 Participants were Swedish males and aged 45 to
79 y and females aged 39 to 76 y from
the population-based Cohort of Swedish Men and
the Swedish Mammography Cohort.
Burazeri, 200326 Prospective cohort study;
Israel; 1985 with up to
11 years’ follow-up
1842 Unclear 46 Participants were aged >50 y in West Jerusalem
in the Kiryat Yovel Community Health Study.
Cai, 201527 Prospective cohort study;
China; 1996–2010
113 138 54 41 Participants were Chinese men and women in
Shanghai, China in the Shanghai Women’s Health
Study and the Shanghai Men’s Health Study.
Canivet, 201428 Prospective cohort study;
Sweden; 1991–2005
13 617 Unclear 43 Participants were all people between the ages of 45
and 65 residing in Malmo, Sweden from the Malmo
Diet and Cancer Study 1991.
Castro-Costa,
201129
Prospective cohort study;
Brazil; 1997–2005
1512 Median 69 38 Participants were all residents of Bambui city, Brazil
aged ≥60 years on January 1, 1997 and part of
the Bambui Cohort Study.
Chandola, 201030 Prospective cohort study;
England; 1985–1988
10 308 Unclear 67 Participants were adults aged 35 to 55 y from
20 London-based civil service departments in the
Whitehall II Cohort.
Chen, 200831 Prospective cohort study;
USA; 1994–1998
93 175 Unclear 0 Participants were postmenopausal women aged 50
to 79 y from all over the United States in the
Women’s Health Initiative Observational
study cohort.
Chen, 201332 Prospective cohort study;
Taiwan; 1999–2002
4064 73.8 56 Participants were residents of the Shih-Pai area of
Taipei, Taiwan who were aged >65 y and
part of the Shih-Pai Sleep Study.
Chien, 201033 Prospective cohort study;
Taiwan; 1990–1991
3430 54.8 50 Participants were adults aged >35 years in the
Chin-Shan Community Cardiovascular Cohort study
and of Chinese ethnicity living in Chin-Shan
township, Taiwan.
Cohen-Mansfeld,
201234
Prospective cohort study;
Israel; 1989–1992
1166 83 55 Participants were older Jewish adults aged
>75 y in the Cross-Sectional and Longitudinal
Aging Study.
Ensrud, 201235 Prospective cohort study;
USA; 2003–2005
2505 76 100 Participants were nonfrail males aged ≥65 y,
recruited by the prospective Osteoporotic Fractures
in Men study.
Gangwisch,
200836
Prospective cohort study;
USA; 1982–1992
9789 Unclear 37 Participants were men and women aged 25 to 74 y
in the NHANES I epidemiological
follow-up study.
Continued
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Table 1. Continued
Study ID Design; Country; Year
No. of
Participants
Mean
Age, y % Male Participant Inclusion Criteria
Garde, 201337 Prospective cohort study;
Denmark; 1970–2001
5249 49 100 Participants were in the Copenhagen Male Study
who were all men aged 40 to 59 y at 14
companies were invited.
Gianfagna, 201638 Prospective cohort study;
Italy; 1986–2008
2277 51 100 Participants were men aged 35 to 74 y and
CVD free in the MONICA-Brianza and PAMELA
population based cohorts.
Goto, 201339 Prospective cohort study;
Japan; 1987–1999
724 Unclear 65 Participants were aged ≥65 y in Okinawa Japan.
Hale, 201340 Prospective cohort study;
USA; 1993–2009
3942 62 0 Participants were in the Women’s Health Initiative
clinical trial and observational study who were
postmenopausal women aged 50 to 79 y and
did not have history of CHD.
Hall, 201541 Prospective cohort study:
USA; 1997 start follow-up
of 9 years
3013 73.6 48.6 Participants were adults in the Health, Aging and
Body Composition Study.
Hamazaki, 201142 Prospective cohort study;
Japan; 1994–2008
2282 44 100 Participants were men aged 35 to 54 y at a
light metal factory (Japan) who did not have
previous cardiovascular events or missing
information at baseline survey.
Helbig, 201543 Prospective cohort study;
Germany; 1984–2001
17 604 48 50 Participants were age 25 to 74 y in the
Monitoring Trends and Determinants in
Cardiovascular Disease/Cooperative Health
Research in the Region of Augsburg study.
Heslop, 200244 Prospective cohort study;
Scotland; 1970–1995
3030 Unclear 85 Participants were working Scottish men and women
recruited between 1970 and 1973.
Hoevenaar-Blom,
201112
Prospective cohort study;
Netherlands; 1993–2012
20 432 42 45 Participants were aged 20 to 65 y in the
MORGEN study.
Huang, 201345 Prospective cohort study;
Taiwan; 1999–2010
1901 Unclear 51 Participants were aged ≥65 y in the Elderly Nutrition
and Health Survey in Taiwan.
Hublin, 200746 Prospective cohort study;
Finland; 1975–2003
21 268 41 48 Participants were in Finnish Twin Cohort who
were all Finnish twin pairs of the same sex born
before 1958 with both co-twins alive in 1975.
Ikehara, 200947 Prospective cohort study;
Japan; 1988–2003
98 634 Unclear 42 Participants were in the Japan Collaborative Cohort
Study for Evaluation of Cancer Risk where were
aged 40 to 79 y and living in Japan.
Jung, 201348 Prospective cohort study;
USA; 1984–2001
2001 74 44 Participants were in the community-dwelling
adults aged 60 to 96 y in The Rancho
Bernardo Study.
Kakizaki, 201349 Prospective cohort study;
Japan; 1994–2008
49 256 60 48 Participants were aged 40 to 79 y in the Ohsaki
Cohort Study.
Kawachi, 201650 Prospective cohort study;
Japan; 1992–2008
27 896 54 54 Participants were men and women aged
≥35 y in the Takayama Cohort Study.
Kim, 201351 Prospective cohort study;
USA; 1993–2007
135 685 Unclear 46 Participants were aged 45 to 75 y in the Multiethnic
Cohort Study from Hawaii and Los Angeles.
Kojima, 200052 Prospective cohort study;
Japan; 1982–1996
5322 47 46 Participants were aged 20 to 76 y from
Shirakawa town, Japan.
Kripke, 200253 Prospective cohort study;
USA; 1982–1988
1 116 936 57 43 Participants were aged 30 to 102 y in the
Cancer Prevention Study II mainly friends/relatives
of American Cancer Society volunteers.
Lan, 200754 3079 71 55
Continued
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Table 1. Continued
Study ID Design; Country; Year
No. of
Participants
Mean
Age, y % Male Participant Inclusion Criteria
Prospective cohort study;
Taiwan; 1993–2003
Participants were ≥64 y in the Survey of Health and
Living Status of the Elderly in Taiwan.
Lee, 201455 Prospective cohort study;
Hong Kong; 2001–2010
3427 74 51 Participants were men and women in Hong Kong
aged ≥65 y.
Lee, 201756 Prospective cohort study;
Taiwan; 2006–2010
937 65 55 Participants were Taiwanese aged ≥53 y in the
Social Environment and Biomarkers of Aging Study.
Leng, 20159 Prospective cohort study;
United Kingdom; 1998–
2009
9692 62 46 Participants were adults aged 42 to 81 y in the
European Prospective Investigation into Cancer-
Norfolk cohort.
Li, 201357 Prospective cohort study;
Japan; 1983–1990
12 489 Unclear 38 Participants were residents aged 20 to 79 y
in the Minami Saku area of Japan who were a
part of the SAKUCESS project.
Liu, 201458 Prospective cohort study;
USA; 1971–2007
3381 45 48 Participants were aged >30 y and were
free from CHD in the Framingham Offspring Study.
Magee, 201159 Prospective cohort study;
Australia; 2006–2009
218 155 63 47 Participants were Australian adults aged ≥45 y,
residing in the state of New South Wales and
part of the 45 and Up study.
Magee, 201360 Prospective cohort study;
Australia; 2006–2009
227 815 Unclear 46.3 Participants were Australian adults aged ≥45 y,
residing in the state of New South Wales and
part of the 45 and Up study.
Mallon, 200261 Prospective cohort study;
Sweden; 1983–1995
1870 56 48 Participants were a random adults aged 45 to
65 y in the population register of the County of
Dalarna in Sweden.
Martin, 201162 Prospective cohort study;
USA; Unclear
245 81 62 Participants were adults aged ≥65 y admitted to
postacute rehabilitation sites in the Los Angeles
area in the USA.
Meisinger,
200763
Prospective cohort study;
Germany; 1984–1995
6896 58 50.9 Participants were German adults aged 45 to 74 y
who were part of the MONICA Augsburg project.
Mesas, 201064 Prospective cohort study;
Spain; 2001–2008
3820 71.8 44 Participants were noninstitutionalized adults aged
≥60 y living in Spain.
Pan, 201465 Prospective cohort study;
Singapore; 1993–1998
63 257 57 44 Participants were Chinese adults in Singapore
aged 45 to 74, recruited from Hokkiens and
Cantonese dialect groups residing in government
housing estates.
Patel, 200466 Prospective cohort study;
USA; 1986–2000
82 969 53 0 Participants were women aged 30 to 55 y
and residing in 11 US states that were part of the
Nurses’ Health Study.
Pollak, 199067 Prospective cohort study;
USA; 1984–1985
1855 75 Unclear Participants were elderly residents of an urban
community aged 65 to 98 y.
Qiu, 201168 Prospective cohort study;
China; 2005–2008
12 671 86 57 Participants were elderly Chinese adults from 22
provinces in China in the Chinese Longitudinal
Healthy Longevity Survey.
Qureshi, 199769 Prospective cohort study;
USA; 1982–1992
7844 Unclear 36 Participants were US civilian noninstitutionalized
adults aged >31 y and in the NHANES I
Epidemiologic Follow-up Study (NHEFS).
Rhee, 201270 Prospective cohort study;
Korea; 1992–2008
14 533 51 100 Participants were male subjects aged 40 to
59 y in the Seoul Male Cohort Study.
Continued
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Table 1. Continued
Study ID Design; Country; Year
No. of
Participants
Mean
Age, y % Male Participant Inclusion Criteria
Rod, 201471 Prospective cohort study;
UK; 1985–2010
9098 45 67 Participants were in the Whitehall II Cohort Study
who were London-based office staff aged 35 to
55 y working in 20 civil service departments
in 1985.
Ruigomez,
199572
Prospective cohort study;
Spain; 1986–1991
1219 Unclear 39 Participants were an elderly population in the 1986
Health Interview Survey of Barcelona.
Ruiter Petrov,
201473
Prospective cohort study;
USA; 2003–2010
5666 61 44 Participants were aged ≥45 y in the Reasons
for Geographic And Racial Differences in
Stroke study.
Sands-Lincoln,
201374
Prospective cohort study;
USA; 1993–2009
86 329 63 0 Participants were in the Women’s Health Initiative
clinical trial and observational study who were
postmenopausal women aged 50 to 79 y
and did not have a history of CHD.
Shankar, 200875 Prospective cohort study;
Singapore; 1993–2006.
58 044 56 44 Participants were Chinese adults aged 45 to
75 y in the Singapore Chinese Health Study.
Song, 201676 Prospective cohort study;
China; 2006–2010
95 203 51 79 Participants were aged 18 to 98 y in the
Kailuan study.
Stone, 200977 Prospective cohort study;
USA; Unclear
6107 80 50 Participants were community-dwelling older adults
participating in the Study of Osteoporotic Fractures
and the Outcomes of Sleep Disorders in Older Men
Study.
Strand, 201678 Prospective cohort study;
Taiwan; 1998–2011
392 164 40 49 Participants were Taiwanese adults aged 20 y
who were participants in a health check-up
program run by MJ Health Management Institution.
Suzuki, 200911 Prospective cohort study;
Japan; 1999–2006
12 601 74 51 Participants were elderly residents aged 65 to
85 y in the Shizuoka Study.
Tamakoshi,
200479
Prospective cohort study;
Japan; 1988–1999
104 010 58 42 Participants were aged 40 to 79 y in the Japan
Collaborative Cohort Study on Evaluation of Cancer
Risk study.
Tsubono, 199380 Prospective cohort study;
Japan; 1988–1992
4318 Unclear 40 Participants were aged ≥40 y in Japan who
participated in the annual health examination
program implemented by the Town Council.
Tu, 201281 Prospective cohort study;
China; 1997–2006
68 832 60 0 Participants were women aged 40 to 70 y in
the Shanghai Women’s Health Study.
Twig, 201682 Prospective cohort study;
Israel; unclear
23 690 30 100 Participants were men aged >25 y in the Israeli
Defense Forces who were in the MELANY cohort
study.
Von Ruesten,
201283
Prospective cohort study;
Germany; 1994–2007
23 620 49 39 Participants were in the European Prospective
Investigation into Cancer and Nutrition (EPIC)
study in Potsdam.
Wang, 201684 Prospective cohort study;
China; 2006–2010
95 903 51 80 Participants were aged 18 to 98 y in the
Kailuan study.
Werle, 201185 Prospective cohort study;
Brazil; 1994–2009
187 84 36 Participants were aged >80 y in the city of
Veranopolis, Brazil.
Westerlund,
20138
Prospective cohort study;
Sweden; 1997–2010
41 192 Unclear 35 Participants were aged ≥18 y in the Swedish
National March Cohort Study.
Wingard, 198386 Prospective cohort study;
USA; 1965–1974
6928 Unclear 47 Participants were aged 30 to 69 y of age
in 1965 in California.
Xiao, 201487 Prospective cohort study;
USA; 1995–2011
239 896 63 56 Participants were aged 51 to 72 y in the NIH AARP
Diet and Health Study.
Continued
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longer sleep durations are associated with greater mortality
compared with small increases for shorter durations. The
similar J-shaped relationship was observed for the subgroup of
men and women.
Sleep Duration and CHD Mortality and CHD
A total of 537,47,49,75,78 and 12*** studies were included in
spline analysis for CHD mortality and CHD, respectively.
Linear spline analysis failed to demonstrate any signiﬁcant
difference for both outcomes for self-reported shorter and
longer sleep durations (Figure 3, cubic model in Data S8).
For the meta-analysis, there were 7 studies37,47,49,51,61,75,78
(Data S11) and 15 studies**** (Data S12) for CHD mortality
and CHD, respectively. Although there were fewer studies, a
similar J-shaped pattern was observed where there was greater
risk of CHD mortality and events with incremental deviation
from the reference 7 to 8 hours of self-reported sleep (amodest
increase for 6 hours and greater increase for ≤5 hours; Data
S10). The funnel plot for self-reported sleep duration and CHD
mortality suggested a possible publication bias whereas for
CHD the plot did not suggest that there was a publication bias.
Sleep Duration and Stroke Mortality and Stroke
Linear spline analysis for stroke mortality and stroke included
347,49,65 and 98,22,31,42,43,50,69,76,83 studies, respectively.
There was no difference in stroke events associated with
self-reported sleep duration shorter or longer than 7 hours,
but a moderate increase in stroke mortality if sleep duration
was >7 hours (Figure 3, Data S8).
Meta-analysis of 5 studies27,47,49,51,65 were included in the
analysis of stroke mortality (Data S10). For stroke events,
there were 13 studies.† The funnel plot for sleep duration and
stroke mortality did not suggest a publication bias. For stroke
mortality, there appeared to be no difference in events with
self-reported sleep duration <7 hours, but signiﬁcant and
moderate increase in events with longer sleep duration
>8 hours (Data S13). However, for stroke events, the increase
in event rates are preserved for both sleep duration <7 hours
(modest for 6 hours and a greater increase for ≤5 hours) and a
moderate increase for >8 hours (Data S14). The funnel plot for
sleep duration and stroke did not suggest a publication bias.
Sleep Duration and Cardiovascular Mortality and
CVD
Spline analysis using linear models did not shown any
difference in events with shorter duration than 7 hours for
both cardiovascular mortality (8 studies)11,25,44,47,49,71,87,88
and CVD (7 studies).8,12,22,33,38,42,74 However, longer self-
reported sleep duration >7 hours appeared to be associated
with a moderate increase in greater stroke mortality (cubic
model shown in Data S8).
There were 16 studies‡ (Data S15) that evaluated CVD
mortality and 8 studies8,12,22,28,33,38,42,74 (Data S16) that
evaluated CVD events. The J-shaped pattern was observed for
self-reported sleep duration and CVD mortality, but this was
not the case for CVD events, but there were fewer studies in
the event analysis. The funnel plot for sleep duration and CVD
mortality and CVD did not suggest a publication bias.
Incremental decrease in hours of sleep was associated with
signiﬁcant increase in mortality (Data S10).
Sleep Quality and Mortality and Adverse
Cardiovascular Outcomes
A total of 17 studies§ were included in the analysis of
subjective sleep quality and adverse outcomes (Data S10 and
Data S17). For all-cause mortality, there were 12 652 deaths
Table 1. Continued
Study ID Design; Country; Year
No. of
Participants
Mean
Age, y % Male Participant Inclusion Criteria
Yeo, 201388 Prospective cohort study;
Korea; 1993–2010
13 164 55 41 Participants were aged ≥20 y in the Korean Multi-
center Cancer Cohort study.
Zawisza, 201589 Prospective cohort study;
Poland; 1986–2008
2449 72 35 Participants were aged ≥65 y from Krakow city
centre in Poland.
Zuubier, 201590 Prospective cohort study;
Netherlands; 2004–2013
1734 62 47 Participants were aged ≥45 y in the Rotterdam
Study.
CHD indicates coronary heart disease; CVD, cardiovascular disease; MELANY, Metabolic Lifestyle and Nutrition Assessment in Young Adults; MONICA-Brianza, Monitoring of
Cardiovascular Disease-Brianza; MORGEN, Monitoring Project on Risk Factors and Chronic Diseases in the Netherlands; NHANES, National Health and Nutrition Examination Survey;
PAMELA, Pressioni Arteriose Monitorate E Loro Associazioni; SAKUCESS, Saku Cancer Etiology Surveillance Study.
***References 8, 12, 22, 24, 38, 42, 58, 63, 69, 74, 83, 84.
****References 8, 12, 22, 24, 38, 40, 42, 58, 59, 63, 69, 74, 81, 83, 84.
†References 8, 9, 22, 31, 42, 43, 59, 69, 73, 76, 81, 83.
‡References 8, 11, 25–27, 32, 44, 47, 49, 51, 54, 57, 66, 71, 87, 88.
§References 8, 11, 12, 30, 32, 35, 38, 43, 45, 46, 52, 61–63, 68, 71, 78, 82.
DOI: 10.1161/JAHA.118.008552 Journal of the American Heart Association 8
Sleep Duration and Quality and CVD and Mortality Kwok et al
S
Y
S
T
E
M
A
T
IC
R
E
V
IE
W
A
N
D
M
E
T
A
-A
N
A
L
Y
S
IS
D
ow
nloaded from
 http://ahajournals.org by on August 24, 2018
Table 2. Study Cohort, Follow-up and Results for Studies With Authors Akersted to Akersted
Study ID Follow-up Duration
Outcomes and Crude Rate
of Outcomes Results
Akersted, 201721 13 y All-cause mortality:
3548/39 191
Sleep duration and mortality: ≤5 h: aHR 1.12 (0.99–1.27),
6 h: aHR 0.98 (0.88–1.09), 7 h: aHR 1.00, ≥8 h: aHR 1.10 (1.00–
1.20).
Amagai, 201022 10.7 y CVD events: 481/
11 367. MI: 80/
11 367. Stroke: 411/
11 367
Sleep duration and CVD in males: <5.9 h: aHR 2.14 (1.11–4.13), 6.0
to 6.9 h: aHR 1.04 (0.61–1.76), 7.0 to 7.9 h: aHR
1.00, 8.0 to 8.9 h: aHR 0.98 (0.69–1.40), ≥9.0 h:
aHR 1.33 (0.93–1.92).
Sleep duration and CVD in females: <5.9 h: aHR 1.46
(0.70–3.04), 6.0 to 6.9 h: aHR 0.64 (0.38–1.10), 7.0 to 7.9 h: aHR
1.00, 8.0 to 8.9 h: aHR 0.85 (0.60–1.20), ≥9.0 h: aHR 1.28 (0.88–
1.87).
Sleep duration and MI in men: <5.9 h: aHR 1.78 (0.50–6.28),
6.0 to 6.9 h: aHR 0.77 (0.25–2.33), 7.0 to 7.9 h: aHR
1.00, 8.0 to 8.9 h: aHR 0.69 (0.34–1.41), ≥9.0 h:
aHR 0.99 (0.47–2.06).
Sleep duration and MI in women: <5.9 h: aHR 4.93
(1.31–18.61), 6.0 to 6.9 h: aHR 0.59 (0.13–2.73), 7.0 to 7.9 h:
aHR 1.00, 8.0 to 8.9 h: aHR 0.59 (0.21–1.66), ≥9.0 h: aHR 0.84
(0.27–2.62).
Sleep duration and stroke in men: <5.9 h: aHR 2.00
(0.93–4.31), 6.0 to 6.9 h: aHR 1.13 (0.63–2.03), 7.0 to 7.9 h: aHR
1.00, 8.0 to 8.9 h: aHR 1.03 (0.69–1.53), ≥9.0 h: aHR 1.39 (0.92–
2.10).
Sleep duration and stroke in women: <5.9 h: aHR 0.97
(0.39–2.41), 6.0 to 6.9 h: aHR 0.68 (0.39–1.18), 7.0 to 7.9 h: aHR
1.00, 8.0 to 8.9 h: aHR 0.86 (0.60–1.23), ≥9.0 h: aHR 1.29 (0.86–
1.91).
Aurora, 201623 10.8 y All-cause mortality:
1509/5784
Sleep duration and mortality: <7 h: aHR 0.98 (0.87–1.10), 7 to 8 h:
aHR 1.00, ≥9 h: aHR 1.25 (1.05–1.47).
Ayas, 200324 10 y CHD: 934/71 617 Sleep duration and CHD: ≤5 h: aOR 1.39 (1.05–1.84), 6 h:
aOR 1.18 (0.98–1.43), 7 h: aOR 1.10 (0.92–1.31), 8 h:
aOR 1.00, >9 h: aOR 1.37 (1.02–1.85).
Bellavia, 201425 15 y All-cause mortality
13 450/70 973. CVD
mortality: 3981/
70 973
Sleep duration and all-cause mortality: <6 h: aHR 1.25
(1.13–1.37), 6 to 6.5 h: aHR 1.10 (1.04–1.17), 6.6 to
7.4 h: aHR 1.00 (reference), 7.5 to 8 h: aHR 1.03
(0.98–1.08), >8 h: aHR 1.14 (1.05–1.24).
Sleep duration and CVD mortality: <6 h: aHR 1.44 (1.20 to 1.73),
6 to 6.5 h: aHR 1.23 (1.09–1.38), 6.6 to 7.4 h: aHR 1.00,
7.5 to 8 h: aHR 1.02 (0.92–1.12), >8 h: aHR 1.11
(0.95–1.31).
Burazeri, 200326 10 y All-cause mortality: 403/
1842
Total sleep duration and all-cause mortality in men: <6 h: aHR 1.00,
6 to 8 h: aHR 1.41 (0.83–2.39), >8 h: aHR 2.13
(1.23–3.71).
Total sleep duration and all-cause mortality in women: <6 h: aHR 1.00,
6 to 8 h: aHR 0.63 (0.42–0.97), >8 h: aHR 0.80 (0.51–1.24).
Total sleep duration and CVD mortality in men: <6 h: aHR 1.00, 6 to 8 h:
aHR 1.54 (0.75–3.15), >8 h: aHR 2.02 (1.01–4.03).
Total sleep duration and CVD mortality in women: <6 h: aHR 1.00,
6 to 8 h: aHR 0.69 (0.37–1.29), >8 h: aHR 0.79 (0.42–1.48).
Cai, 201527 Median 6 to 7 y All-cause mortality:
4277/113 138
Sleep duration and all-cause mortality: 4 to 5 h: aHR 1.11
(1.00–1.23), 6 h: aHR 1.06 (0.97–1.16), 7 h: aHR 1.00, 8 h: aHR
1.15 (1.05–1.26), 9 h: aHR 1.34 (1.17–1.54), ≥10 h: 1.81
(1.59–2.06).
Sleep duration and all-cause mortality in men: 4 to 5 h: aHR
1.06 (0.90–1.25), 6 h: aHR 1.07 (0.94–1.23), 7 h: aHR
Continued
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Table 2. Continued
Study ID Follow-up Duration
Outcomes and Crude Rate
of Outcomes Results
1.00, 8 h: aHR 1.13 (1.00–1.28), 9 h: aHR
1.34 (1.10–1.62), ≥10 h: aHR 1.55 (1.29–1.86).
Sleep duration and all-cause mortality in women: 4 to 5 h: aHR 1.15
(1.01–1.32), 6 h: aHR 1.06 (0.94–1.20), 7 h: aHR
1.00, 8 h: aHR 1.17 (1.04–1.32), 9 h: aHR
1.36 (1.13–1.64), ≥10 h: aHR 2.11 (1.77–2.52).
Sleep duration and cardiovascular mortality: 4 to 5 h: aHR 1.05 (0.87–
1.26), 6 h: aHR 1.10 (0.94–1.29), 7 h: aHR 1.00, 8 h: aHR 1.22 (1.05
–1.43), 9 h: aHR 1.47 (1.17–1.85), ≥10 h: aHR 2.04 (1.65–2.53).
Sleep duration and cardiovascular mortality in men: 4 to 5 h:
aHR 1.09 (0.82–1.46), 6 h: aHR 1.06 (0.83–1.34), 7 h:
aHR 1.00, 8 h: aHR 1.25 (1.00–1.56), 9 h: aHR 1.68
(1.23–2.30), ≥10 h: aHR 1.58 (1.14–2.18).
Sleep duration and cardiovascular mortality in women: 4 to 5 h: aHR
1.02 (0.80–1.30), 6 h: aHR 1.12 (0.91–1.39), 7 h:
aHR 1.00, 8 h: aHR 1.20 (0.96–1.50), 9 h: aHR 1.28
(0.91–1.82), ≥10 h: aHR 2.64 (1.99–3.52).
Sleep duration and stroke mortality: 4 to 5 h: aHR 0.91
(0.70–1.18), 6 h: aHR 0.99 (0.79–1.23), 7 h: aHR 1.00, 8 h: aHR
1.28 (1.04–1.58), 9 h: aHR 1.31 (0.94–1.82), ≥10 h: aHR 2.35
(1.78–3.09).
Sleep duration and stroke mortality in men: 4 to 5 h: aHR 0.93 (0.62–
1.40), 6 h: aHR 0.78 (0.55–1.10), 7 h: aHR 1.00, 8 h: 1.20 (0.89–
1.62), 9 h: aHR 1.62 (1.06–2.48), ≥10 h: aHR 1.73 (1.14–2.64).
Sleep duration and stroke mortality in women: 4 to 5 h:
aHR 0.92 (0.65–1.29), 6 h: aHR 1.14 (0.85–1.52),
7 h: aHR 1.00, 8 h: aHR 1.36 (1.01–1.82), 9 h:
aHR 0.98 (0.58–1.66), ≥10 h: aHR 3.09 (2.14–4.47).
Canivet, 201428 14 y Unclear Sleep duration and cardiovascular events in men: ≤6 h: aHR 1.1
(0.96–1.3), 7 to 8 h: aHR 1.0, ≥9 h:aHR 1.3 (1.01–1.7).
Sleep duration and cardiovascular events in women: ≤6 h:
aHR 1.3 (1.1–1.5), 7 to 8 h: aHR 1.0, ≥9 h: aHR 1.5
(1.1–2.1).
Castro-Costa,
201129
Unclear All-cause mortality: 440/
1512
Night-time sleep duration and all-cause mortality: <6 h: aHR
1.09 (0.78–1.53), 6 to 7 h: aHR 0.84 (0.60–1.17), 7 to
8 h: aHR 1.00 (reference), 8 to 9 h: aHR 1.31 (0.97–1.78), ≥9 h:
aHR 1.53 (1.12–2.09).
Chandola, 201030 15 y CHD mortality, MI,
angina: 1205/8998
Sleep duration and CHD mortality, MI and angina: <5 h: aRR
1.05 (0.92–1.20), 6 h: aRR 0.98 (0.83–1.16), 7 h: aRR
1.00, >8: aRR 0.99 (0.77–1.27).
Poor sleep quality (more than usual restless, disturbed nights)
and CHD mortality, MI, and angina: aRR 1.36 (1.10–1.68).
Chen, 200831 7.5 y Ischaemic stroke: 1166/
93 175
Sleep duration and ischemic stroke: <6 h: aHR 1.14 (0.97–1.33), 7
h: aHR 1.00, 8 h: aHR 1.24 (1.04–1.47), >9 h: aHR 1.70 (1.32–2.21).
Chen, 201332 9 y All-cause mortality:
1004/4064. CVD
mortality: 259/4064
Sleep duration and all-cause mortality: <4 h: aHR 1.00
(0.75–1.33), 5 h: aHR 0.92 (0.74–1.15), 6 h: aHR 0.88
(0.73–1.06), 7 h: aHR 1.00, 8 h: aHR 1.26 (1.04–1.53), >9 h: aHR
1.66 (1.28–2.17).
Sleep duration and CVD mortality: <4 h: aHR 1.05 (0.61–1.79), 5 h:
aHR 0.95 (0.62–1.48), 6 h:aHR 0.79 (0.54–1.16), 7 h: aHR 1.00, 8
h: aHR 1.36 (0.92–2.01), >9 h: aHR 2.36 (1.46–3.80).
Poor sleep quality (subjective) and all-cause mortality: aHR 0.81
(0.47–1.38).
Poor sleep quality (subjective) and CVD mortality: aHR 0.60
(0.19–1.93).
Continued
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Table 2. Continued
Study ID Follow-up Duration
Outcomes and Crude Rate
of Outcomes Results
Chien, 201033 Median 15.9 y All-cause mortality: 901/
3430. CVD events:
420/3430
Sleep duration and all-cause mortality: <5 h: aRR 1.15
(0.9–1.46), 6 h: aRR 0.97 (0.79–1.21), 7 h: aRR 1,
8 h: aRR 1.04 (0.86–1.27), ≥9 h: aRR 1.34 (1.08–1.67).
Sleep duration and CVD event: <5 h: aRR 0.94 (0.65–1.35), 6 h:
aRR 0.91 (0.67–1.24), 7 h: aRR 1, 8 h: aRR 1.05 (0.80–1.39), >9
h: aRR 1.12 (0.81–1.55).
Cohen-Mansfeld,
201234
20 y All-cause mortality:
1108/1166
Sleep duration and mortality: <7 h: aHR 0.98 (0.84–1.13), 7 to 9 h:
1.00, >9 h: aHR 1.32 (1.09–1.58).
Ensrud, 201235 3.4 y All-cause mortality: 180/
2505
Poor sleep quality (PSQI score >5) and all-cause mortality:
>5 81/1018 vs ≤5 99/1487, aOR 1.02 (0.73–1.42).
Sleep duration and all-cause mortality: ≤5 h: 21/269
vs 159/2236, aOR 1.08 (0.65–1.80).
Gangwisch, 200836 Up to 10 y All-cause mortality:
1877/9789
Sleep duration and all-cause mortality: ≤5 h: aHR 1.17
(0.99–1.39), 6 h: aHR 0.95 (0.81–1.11), 7 h: aHR 1.00, 8 h: aHR
1.23 (1.08–1.39), ≥9 h: aHR 1.34 (1.15–1.56).
Garde, 201337 30 y All-cause mortality:
2643/5249. Ischaemic
heart disease mortality:
587/5249
Sleep duration on all-cause mortality in men: <6 h: aHR 1.06
(0.90–1.25). 6 to 7 h: aHR 1.00. ≥8 h: aHR 0.99 (0.84 to 1.09).
Sleep duration and ischemic heart disease mortality in men:
<6 h: aHR 1.46 (1.07–2.00). 6 to 7 h: aHR 1.00.
≥8 h: aHR 1.20 (0.97–1.49).
Gianfagna, 201638 Median 17 y CVD event: 293/2277.
CHD event: 214/2277
Sleep duration and CVD event: ≤6 h: aHR 1.14 (0.84–1.53),
7 to 8 h: aHR 1.00, ≥9 h: aHR 1.55 (1.08–2.21).
Sleep duration and CHD event: ≤6 h: aHR 1.14 (0.80–1.61),
7 to 8 h: aHR 1.00, ≥9 h: aHR 1.32 (0.85–2.07).
Sleep disturbance on CVD event vs none/some: moderate aHR 1.14
(0.74–1.77), severe aHR 1.80 (1.07–3.03).
Sleep disturbance on CHD event vs none/some: moderate aHR 1.35
(0.83–2.21), severe aHR 1.83 (0.98–3.41).
Goto, 201339 12 y All-cause mortality: 305/
724
Sleep duration and all-cause mortality in men: aHR <6 h:
aHR 1.29 (0.50–3.34), 6 to 7 h: aHR 1.00, >7 h: aHR
1.54 (092–2.58).
Sleep duration and all-cause mortality in women: aHR <6 h:
aHR 2.62 (1.36–5.07), 6 to 7 h: aHR 1.00, >7 h: aHR
1.40 (0.91–2.15).
Hale, 201340 Up to 16 y All-cause mortality: 335/
3942. CHD: 132/3942
Sleep duration and all-cause mortality: ≤5 h: aOR 1.01
(0.68–1.51), 6 h: aOR 0.94 (0.71–1.24), 7 to 8 h:
aOR 1.00, ≥9 h: aOR 1.55 (0.92–2.60).
Sleep duration and CHD: ≤5 h: aOR 1.09 (0.63–1.89), 6 h:
aOR 0.66 (0.42–1.04), 7 to 8 h: aOR 1.00, ≥9 h: aOR
1.88 (0.92–3.83).
Hall, 201541 9 y All-cause mortality: 953/
3075
Sleep duration and all-cause mortality: <6 h: aHR 1.06
(0.83–1.34), 6 h: aHR 1.00 (0.82–1.22), 7 h: aHR 1.00, 8 h: aHR
1.10 (0.91–1.33), >8 h: aHR 1.23 (0.93–1.63).
Hamazaki, 201142 14 y CVD events: 64/2282.
Stroke: 30/2282.
Coronary events: 27/
2282
Sleep duration and CVD events: <6 h: aHR 3.49 (1.30–9.40),
6 to 6.9 h: aHR 1.11 (0.55–2.25), 7 to 7.9 h: aHR 1.00, ≥8 h:
aHR 1.71 (0.90–3.24).
Sleep duration and stroke: <6 h: aHR 1.84 (0.23–14.90),
6 to 6.9 h: aHR 0.96 (0.30–3.10), 7 to 7.9 h: aHR 1.00, ≥8 h:
aHR 2.25 (0.91–5.57).
Sleep duration and coronary events: <6 h: aHR 4.95
(1.31–18.73), 6 to 6.9 h: aHR 1.12 (0.40–3.13), 7 to
7.9 h: aHR 1.00 (reference), ≥8 h: aHR 1.78 (0.67–4.76).
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Table 2. Continued
Study ID Follow-up Duration
Outcomes and Crude Rate
of Outcomes Results
Helbig, 201543 14 y Stroke: 917/17 604 Sleep duration and strokes in men: ≤5 h: aHR 1.36 (0.95–1.94), 6 h:
aHR 0.92 (0.70–1.22), 7 to 8 h: aHR 1.00, 9 h:
aHR 1.05 (0.78–1.43), ≥10 h: aHR 1.38 (0.98–1.94).
Sleep duration and strokes in women: ≤5 h: aHR 0.68
(0.40–1.18), 6 h: aHR 1.25 (0.91–1.70), 7 to 8 h:
aHR 1.00, 9 h: aHR 1.09 (0.76–1.57), ≥10 h:
aHR 0.91 (0.55–1.51).
Poor sleep quality (difficulty staying asleep) and stroke in men:
aHR 1.06 (0.87–1.30).
Poor sleep quality (difficulty staying asleep) and stroke in women:
aHR 0.87 (0.68–1.10).
Heslop, 200244 25 y All-cause mortality:
1062/7028. CVD
mortality: 557/7028
Sleep duration and all-cause mortality in men: <7 h: aHR 1.15
(0.93–1.42), 7 to 8 h: aHR 1.00, >8 h: aHR 0.91
(0.57–1.46).
Sleep duration and all-cause mortality in women: <7 h: aHR
1.73 (0.99–3.03), 7 to 8 h: 1.00, >8 h: aHR 0.58
(0.08–4.22).
Sleep duration and CVD mortality in men: <7 h: aHR 1.19
(0.90–1.58), 7 to 8 h: aHR 1, >8 h: aHR 0.63 (0.30–1.34).
Sleep duration and CVD mortality in women: <7 h: aHR 2.30
(0.94–5.60), 7 to 8 h: aHR 1, >8 h: aHR 1.53 (0.20–11.8).
Hoevenaar-Blom,
201112
11.9 y CVD events: 1486/
20 432. CHD: 1148/
20 432
Sleep duration on incident CVD: ≤6 h: aHR 1.11 (0.97–1.27), 7 h:
aHR 1.00, 8 h: aHR 0.95 (0.84–1.08), ≥9 h: aHR 0.96 (0.77–1.18).
Sleep duration and incident CHD: ≤6 h: aHR 1.19 (1.00–1.40), 7 h:
aHR 1.00, 8 h: aHR 0.85 (0.73–1.00), ≥9 h: aHR 0.78 (0.58–1.04).
Poor sleep quality and incident CVD: aHR 1.04 (0.87–1.26).
Poor sleep quality and incident CHD: aHR 1.19 (0.96–1.50).
Huang, 201345 10 y All-cause mortality: 182/
1865
Poor sleep quality (good vs poor) and all-cause mortality in men:
aHR 0.60 (0.42–0.87).
Poor sleep quality (good vs poor) and all-cause mortality in women:
aHR 0.99 (0.68–1.45).
Hublin, 200746 22 y All-cause mortality:
3700/21 268
Sleep duration and all-cause mortality in men: <7 h: aHR 1.26
(1.11–1.43), 7 to 8 h: aHR 1.00, >8 h: aHR 1.24
(1.09–1.41).
Sleep duration and all-cause mortality in women: <7 h: aHR
1.21 (1.05–1.40), 7 to 8 h: aHR 1.00, >8 h: aHR 1.17
(1.03–1.34).
Poor sleep quality and all-cause mortality in men: aHR 1.10
(0.87–1.39).
Poor sleep quality and all-cause mortality in women: aHR 0.99
(0.77–1.27).
Ikehara, 200947 Median 14.3 y All-cause mortality
14 540/98 634. CVD
mortality 4287/
98 634. Stroke
mortality: 1964/
98 634. CHD mortality
881/98 634
Sleep duration and all-cause mortality in men: ≤4 h: aHR 1.29
(1.02–1.64), 5 h: aHR 1.02 (0.90–1.16), 6 h: aHR 1.08
(1.00–1.16), 7 h: aHR 1.00, 8 h: aHR 1.06 (1.00–1.12), 9 h: aHR
1.13 (1.05–1.22), ≥10 h: aHR 1.41 (1.29–1.54).
Sleep duration and all-cause mortality in women: ≤4 h:
aHR 1.28 (1.03–1.60), 5 h: aHR 1.11 (0.98–1.25), 6 h:
aHR 1.05 (0.97–1.14), 7 h: aHR 1.00, 8 h: aHR 1.16
(1.08–1.24), 9 h: aHR 1.32 (1.20–1.45), ≥10 h: aHR 1.56 (1.40–
1.75).
Sleep duration and CVD mortality in men: ≤4 h: aHR 1.11
(0.67–1.83), 5 h: aHR 0.99 (0.77–1.27), 6 h: aHR 1.01
(0.87–1.18), 7 h: aHR 1.00, 8 h: aHR 1.11 (1.00–1.24), 9 h: aHR
1.14 (0.99–1.32), ≥10 h: aHR 1.56 (1.33–1.83).
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Table 2. Continued
Study ID Follow-up Duration
Outcomes and Crude Rate
of Outcomes Results
Sleep duration and CVD mortality in women: ≤4 h: aHR 1.28
(0.88–1.86), 5 h: aHR 1.22 (1.00–1.50), 6 h: aHR 1.00
(0.86–1.16), 7 h: aHR 1.00, 8 h: aHR 1.28 (1.14–1.44), 9 h: aHR
1.37 (1.17–1.62), ≥10 h: aHR 1.54 (1.28–1.86).
Sleep duration and stroke mortality in men: ≤4 h: aHR 1.56
(0.82–2.94), 5 h: aHR 0.85 (0.58–1.26), 6 h: aHR 0.95
(0.76–1.20), 7 h: aHR 1.00, 8 h: aHR 1.11 (0.95–1.30), 9 h: aHR
1.14 (0.92–1.42), ≥10 h: aHR 1.66 (1.31–2.08).
Sleep duration and stroke mortality in women: ≤4 h: aHR 1.07
(0.59–1.91), 5 h: aHR 0.99 (0.72–1.37), 6 h: aHR 0.93
(0.75–1.16), 7 h: aHR 1.00, 8 h: aHR 1.24 (1.05–1.47), 9 h: aHR
1.29 (1.01–1.64), ≥10 h: aHR 1.69 (1.29–2.20).
Sleep duration and CHD mortality in men: ≤4 h: aHR 0.29
(0.04–2.05), 5 h: aHR 1.02 (0.62–1.70), 6 h: aHR 0.86
(0.63–1.19), 7 h: aHR 1.00, 8 h: aHR 1.02 (0.82–1.27), 9 h: aHR
0.96 (0.70–1.31), ≥10 h: aHR 1.12 (0.77–1.63).
Sleep duration and CHD mortality in women: ≤4 h: aHR 2.32
(1.19–4.50), 5 h: aHR 1.64 (1.07–2.53), 6 h: aHR 1.23
(0.88–1.72), 7 h: aHR 1.00, 8 h: aHR 1.24 (0.94–1.64), 9 h: aHR
1.52 (1.05–2.19), ≥10 h: aHR 1.04 (0.63–1.72).
Jung, 201348 Up to 19 y All-cause mortality:
1224/2001
Night-time sleep duration and all-cause mortality in men: <6 h: aHR
0.98 (0.673–1.43), 6.0 to 6.9 h: aHR 1.12 (0.85–1.48)
7.0–7.9 h: aHR 1.0, 8.0–8.9 h: aHR 0.98 (0.79–1.22), ≥9 h: aHR
1.09 (0.82–1.45).
Night-time sleep duration and all-cause mortality in women:
<6 h: aHR 1.11 (0.77–1.60), 6.0–6.9 h: aHR 1.17
(0.85–1.61) 7.0–7.9 h: aHR 1.0, 8.0–8.9 h: aHR 1.19
(0.90–1.57), ≥9 h: aHR 1.51 (1.05–2.18).
Kakizaki, 201349 13 y All-cause mortality
8447/49 256. CVD
mortality 2549/
49 256. Stroke
mortality 1165/
49 256. IHD mortality
561/49 256
Sleep duration and all-cause mortality: ≤6 h: aHR 1.01
(0.93–1.09), 7 h: aHR 1.00, 8 h: aHR 1.07 (1.01–1.14), 9 h: aHR
1.14 (1.06–1.24), ≥10 h: aHR 1.37 (1.27–1.47).
Sleep duration on CVD mortality: ≤6 h: aHR 1.10 (0.96–1.28), 7 h:
aHR 1.00, 8 h: aHR 1.21 (1.08–1.36), 9 h:
aHR 1.32 (1.15–1.52), ≥10 h: aHR 1.49 (1.30–1.71).
Sleep duration and stroke mortality: ≤6 h: aHR 1.05
(0.84–1.30), 7 h: aHR 1.00, 8 h: aHR 1.17 (0.99–1.39), 9 h: aHR
1.30 (1.06–1.60), ≥10 h: aHR 1.51 (1.24–1.85).
Sleep duration and IHD mortality: ≤6 h: aHR 1.38 (1.02–1.86), 7 h:
aHR 1.00, 8 h: aHR 1.36 (1.06–1.73), 9 h:
aHR 1.49 (1.10–2.02), ≥10 h: aHR 1.41 (1.04–1.92).
Kawachi 201650 Up to 16 y Stroke mortality: 611/
27 896
Sleep duration and stroke mortality: ≤6 h: aHR 0.77 (0.59–1.01), 7 h:
aHR 1.00, 8 h: aHR 1.13 (0.91–1.40), ≥9 h: aHR 1.51 (1.16–1.97).
Sleep duration and stroke mortality in men: ≤6 h: aHR 0.51
(0.34–0.77), 7 h: aHR 1.00, 8 h: aHR 0.88 (0.66–1.17), ≥9 h: aHR
1.23 (0.90–1.69).
Sleep duration and stroke mortality in women: ≤6 h: aHR 1.06 (0.75–
1.50), 7 h: aHR 1.00, 8 h: aHR 1.50 (1.10–2.04), ≥9 h: aHR 1.93
(1.38–2.70).
Kim, 201351 13 y All-cause mortality:
19 335/135 685. CVD
mortality 6610/
135 685. Stroke
mortality: 1259/
135 685. MI mortality:
1188/135 685
Sleep duration and all-cause mortality in men: aHR ≤5 h: 1.15
(1.06–1.23), 6 h: aHR 1.04 (0.99–1.10), 7 h: aHR 1.00, 8 h: 1.07
(1.01–1.12), ≥9 h: 1.19 (1.12–1.27).
Sleep duration and all-cause mortality in women: aHR ≤5 h:
1.14 (1.06–1.23), 6 h: aHR 1.05 (0.99–1.12), 7 h:
aHR 1.00, 8 h: 1.02 (0.96–1.08), ≥9 h: 1.22 (1.13–1.31).
Sleep duration and CVD mortality in men: aHR ≤5 h: 1.13
(1.00–1.28), 6 h: aHR 1.01 (0.92–1.11), 7 h: aHR 1.00, 8 h: 1.05
(0.96–1.14), ≥9 h: 1.22 (1.09–1.35).
Continued
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Table 2. Continued
Study ID Follow-up Duration
Outcomes and Crude Rate
of Outcomes Results
Sleep duration and CVD mortality in women: aHR ≤5 h: 1.20
(1.05–1.36), 6 h: aHR 1.06 (0.96–1.18), 7 h: aHR 1.00, 8 h: 1.08
(0.98–1.20), ≥9 h: 1.29 (1.13–1.47).
Sleep duration and stroke mortality in men: aHR ≤5 h: 1.02
(0.74–1.40), 6 h: aHR 1.10 (0.88–1.37), 7 h: aHR 1.00, 8 h: 1.13
(0.91–1.39), ≥9 h: 1.35 (1.03–1.75).
Sleep duration and stroke mortality in women: aHR ≤5 h: 1.16
(0.88–1.52), 6 h: aHR 0.99 (0.79–1.23), 7 h: aHR 1.00, 8 h: 1.07
(0.87–1.33), ≥9 h: 1.39 (1.06–1.83).
Sleep duration and MI mortality in men: aHR ≤5 h: 1.24
(0.94–1.64), 6 h: aHR 0.92 (0.74–1.15), 7 h: aHR 1.00, 8 h: 0.98
(0.80–1.20), ≥9 h: 1.16 (0.89–1.50).
Sleep duration and MI mortality in women: aHR ≤5 h: 1.18
(0.87–1.59), 6 h: aHR 1.23 (0.96–1.56), 7 h: aHR 1.00, 8 h: 1.10
(0.86–1.40), ≥9 h: 1.29 (0.95–1.75).
Kojima, 200052 12 y All-cause mortality: 256/
5322
Sleep duration and all-cause mortality in men: <7 h: aRR 1.93
(1.12–3.35), 7.0 to 8.9 h: aRR 1.00, 9.0 to 9.9 h: aRR
1.15 (0.74–1.77), ≥10.0 h: aRR 1.77 (0.88–3.54).
Sleep duration and all-cause mortality in women: <7 h:
aRR 0.90 (0.50–1.61), 7.0 to 8.9 h: aRR 1.00, 9.0 to
9.9 h: aRR 1.07 (0.58–1.95), ≥10.0 h: aRR
0.40 (0.06–2.92).
Poor sleep quality (waking up feeling bad) on all-cause mortality
(Male): aRR 1.13 (0.60–2.12).
Poor sleep quality (waking up feeling bad) on all-cause mortality
(Female): aRR 2.03 (1.10–3.74).
Kripke, 200253 Up for 6 y All-cause mortality:
77 640/1 116 936
Sleep duration and all-cause mortality in men: 3 h: aHR 1.19
(0.96–1.47), 4 h: aHR 1.17 (1.06–1.28), 5 h: aHR 1.11
(1.05–1.18), 6 h: aHR 1.08 (1.04–1.11), 7 h: aHR 1.00
(ref), 8 h: aHR 1.12 (1.09–1.15), 9 h: aHR 1.34
(1.28–1.40), ≥10 h: 1.08 (1.01–1.16).
Sleep duration and all-cause mortality in women: 3 h: aHR 1.33
(1.08–1.64), 4 h: aHR 1.11 (1.01–1.22), 5 h: aHR 1.07
(1.01–1.13), 6 h: 1.07 (1.03–1.11), 7 h: aHR 1.00 (ref), 8 h: aHR
1.13 (1.09–1.16), 9 h: 1.23 (1.17–1.28),
≥10 aHR 1.41 (1.34–1.50).
Lan, 200754 8 y All-cause mortality:
1338/3079. CVD
mortality: 379/3079
Sleep duration and all-cause mortality in men: <7 h: aHR 0.98
(0.76–1.25), 7 h: aHR 1.00, 8 h: aHR 1.09 (0.89–1.33), 9 h: aHR
1.14 (0.91–1.42), ≥10 h: aHR 1.51 (1.19–1.92).
Sleep duration and all-cause mortality in women: <7 h:
aHR 1.14 (0.77–1.67), 7 h: aHR 1.00, 8 h: aHR 1.36
(1.01–1.84), 9 h: aHR 1.86 (1.36–2.53), ≥10 h: aHR 2.06 (1.50–
2.83).
Sleep duration and CVD mortality in men: <7 h: aHR 0.91
(0.53–1.57), 7 h: aHR 1.00, 8 h: aHR 1.40 (0.93–2.10) 9 h: aHR
1.26 (0.80–1.98), ≥10 h: aHR 1.81 (1.13–2.89).
Sleep duration and CVD mortality in women: <7 h: aHR 1.07
(0.54–2.15), 7 h: aHR 1.00, 8 h: aHR 1.77 (1.05–2.98), 9 h: aHR
1.75 (1.00–3.07), ≥10 h: aHR 1.85 (1.04–3.27).
Lee, 201455 61.7 months All-cause mortality: 297/
3427
Night time sleep duration ≥10 h and mortality in men: aHR 1.75
(1.09–2.81).
Night time sleep duration ≥10 h and mortality in women:
aHR 2.88 (1.01–8.18).
Lee, 201756 4.7 y. All-cause mortality: 72/
937.
Sleep duration and all-cause mortality: <6 h: aHR 1.21
(0.67–2.17), 6 to 7 h: aHR 1.00, ≥8 h:
aHR 2.11 (1.19–3.76).
Continued
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among 73 702 participants from 10 studies, and the pooled
results suggest that poor subjective quality of sleep was not
associated with signiﬁcant increase in mortality (risk ratio,
1.03; 95% conﬁdence interval, 0.93–1.14). Poor sleep quality
was associated with a signiﬁcant and moderate increase in
coronary heart disease (risk ratio, 1.44 95% conﬁdence
interval, 1.09–1.90) but not for any other outcomes. The
funnel plot for sleep quality did not suggest publication bias.
Sensitivity Analysis Excluding Studies That Did
Not Exclude Baseline CVD, Adjust for Cardiac
Risk Factors, and Adjusted for Snoring or
Obstructive Sleep Apnea
Sensitivity analysis was performed on the meta-analysis data
(Data S18). After exclusion of studies that included partici-
pants with baseline CVD, there was a signiﬁcant increase in
all-cause mortality with longer and shorter self-reported hours
of sleep (small for 6 hours, modest for 5 and 9 hours, and
moderate for 4 and 10 hours) and moderate increase in CVD
mortality and stroke mortality with longer hours of sleep.
Similar observations were found for studies that adjusted for
CVR factors. For the analysis of CHD and stroke, there were
signiﬁcant and moderate increases in events when baseline
CVD was excluded with 5-hour duration of sleep. For the
adjustments for obstructive sleep apnea analysis, some of the
results were no longer statistically signiﬁcant because there
were fewer studies.
Discussion
In this meta-analysis of 60 studies representing over 3 million
participants, we observed that divergence from the recom-
mended 7 to 8 hours of sleep was signiﬁcantly associated
with a moderate increase in mortality and incident CVD. We
observed a J-shaped relationship between sleep duration and
mortality, and incident adverse cardiovascular events were
observed. When spline analysis was applied to evaluate the
incremental association of sleep duration and adverse events,
our results suggest that longer than the recommended
duration of 7 to 8 hours of sleep may be associated with a
moderate degree of harm, compared with those who slept for
durations shorter than that recommended.
Our study provides evidence that may contribute to
important clinical and public health messages. First, we
observed through spline analysis a more-precise estimation
of the risk gradient of CVD and mortality on the greater
side of the recommended 7 to 8 hours of sleep compared
to existing studies. Second, deviations in sleep duration and
quality may be a nonspeciﬁc marker for increased CVR that
might warrant determination of CVR. In particular, clinicians
may need to be aware that the risk gradient appears to be
Table 2. Continued
Study ID Follow-up Duration
Outcomes and Crude Rate
of Outcomes Results
Leng, 20159 9.5 y Stroke 346/9692 Sleep duration and stroke: <6 h: aHR 1.18 (0.91–1.53), 6 to 8 h:
aHR 1.00, >8 h: aHR 1.46 (1.08–1.98).
Sleep duration and stroke in men: <6 h: aHR 1.08 (0.75–1.57),
6 to 8 h: aHR 1.00, >8 h: aHR: 1.21 (0.80–1.82).
Sleep duration and stroke in women: <6 h: aHR
1.25 (10.86–1.83), 6 to 8 h: aHR 1.00, >8 h: aHR:
1.80 (1.13–2.85).
Li, 201357 7 y All-cause mortality: 312/
12 489
Sleep duration and all-cause mortality in men: <5 h: aHR 1.44
(0.65–3.19), 6 h: aHR 0.86 (0.50–1.48), 7 h: aHR1.00, 8 h: aHR
1.05 (0.72–1.53), >9 h: aHR 1.70 (1.07–2.70).
Sleep duration and all-cause mortality in women: <5 h:
aHR 1.01 (0.42–2.39), 6 h: aHR 1.31 (0.78–2.21), 7 h:
aHR 1.00, 8 h: aHR 1.01 (0.63–1.60), >9 h: aHR 1.85
(1.09–3.13).
Sleep duration and CVD mortality in men: <5 h: aHR 1.57
(0.35–7.15), 6 h: aHR 0.60 (0.17–2.15), 7 h: aHR 1.00, 8 h: aHR
1.04 (0.49–2.21), >9 h: aHR 2.73 (1.22–6.11).
Sleep duration and CVD mortality in women: <5 h: aHR 0.80
(0.18–3.47), 6 h: aHR 0.91 (0.38–2.23), 7 h: aHR 1.00, 8 h: aHR
1.13 (0.57–2.23), >9 h: aHR 1.72 (0.76–3.89).
Liu, 201458 Over 20 y CHD: 491/3381 Sleep duration and CHD: ≤6 h: aHR 1.29 (1.03–1.61), 7 to
8 h: aHR 1.00, ≥9 h: aHR 1.13 (0.81–1.58).
aHR indicates adjusted hazard ratio; aOR, adjusted odds ratio; aRR, adjusted risk ratio; CHD, coronary heart disease; CVD, cardiovascular disease; IHD, ischemic heart disease; MI,
myocardial infarction; PSQI, Pittsburgh Sleep Quality Index.
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Table 3. Study Cohort, Follow-up and Results for Studies With Authors Magee to Zuubier
Study ID Follow-up Duration Outcomes and Crude Rate of Outcomes Results
Magee, 201159 Unclear Stroke 6541/218 155. Heart
disease 25 669/218 155
Sleep duration and stroke: <6 h: aOR 1.54 (1.36–1.75), 6 h: aOR
1.25 (1.14–1.38), 7 h: aOR 1.00, 8 h: aOR 1.08 (1.01–1.17), ≥9 h:
1.50 (1.38–1.62).
Sleep duration and heart disease: <6 h: aOR 1.23 (1.15–1.33), 6 h:
aOR 1.11 (1.06–1.17), 7 h: aOR 1.00, 8 h: aOR 1.01 (0.97–1.05),
≥9 h: aOR 1.14 (1.09–1.19).
Magee, 201360 2.8 y All-cause mortality 8782/227 815 Sleep duration and all-cause mortality: <6 h: aHR 1.13 (1.01–1.25),
6 h: aHR 0.99 (0.91–1.06), 7 h: aHR 1.00, 8 h: aHR 1.02 (0.96–
1.08), 9 h: aHR 1.04 (0.96–1.12), >10 h: aHR 1.26 (1.16–1.36).
Mallon, 200261 12 y All-cause mortality 266/2663.
Coronary artery disease mortality:
91/2663.
Sleep duration and all-cause mortality in men: <6 h: aRR 1.1 (0.6–
7.0), 7 to 8 h: aRR 1.00, >8 h: aRR 2.0 (1.2–3.2).
Sleep duration and all-cause mortality in women: <6 h: aRR 1.0 (0.6
–1.8), 7 to 8 h: aRR 1.00, >8 h: aRR 1.3 (0.6–2.6).
Sleep duration and coronary artery disease mortality in men: <6 h:
aRR 0.7 (0.3–1.7), 7 to 8 h: aRR 1.00, >8 h: aRR 2.2 (1.0–4.4).
Sleep duration and coronary artery disease mortality in women: <6 h:
aRR 1.2 (0.4–4.2), 7 to 8 h: aRR 1.00, >8 h: aRR 0.7 (0.1–5.2).
Poor sleep quality (difficulty maintaining sleep) and all-cause mortality
in men: aRR 1.4 (1.1–1.9).
Poor sleep quality (difficulty maintaining sleep) and coronary artery
disease mortality in men: aRR 1.2 (0.7–1.9).
Poor sleep quality (difficulty maintaining sleep) and all-cause mortality
in women: aRR 1.1 (0.7–1.7).
Poor sleep quality (difficulty maintaining sleep) and coronary artery
disease mortality in women: aRR 1.1 (0.5–2.9).
Martin, 201162 1 y All-cause mortality: 57/245 Sleep quality (high PQSI 7-day score) and all-cause mortality: aHR
1.12 (1.04–1.21).
Meisinger, 200763 Unclear Acute coronary event: 295/6896 Sleep duration and acute coronary event in men: ≤5 h: aHR 1.13
(0.66–1.92), 6 h: aHR 1.05 (0.71–1.55), 7 h: aHR 1.22 (0.92–
1.61), 8 h: aHR 1.00 (reference), ≥9 h: aHR 1.07 (0.75–1.53).
Sleep duration and acute coronary event in women: ≤5 h: aHR 2.98
(1.48–6.03), 6 h: aHR 1.05 (0.49–2.27), 7 h: aHR 1.34 (0.75–
2.40), 8 h: aHR 1.00 (reference), ≥9 h: aHR 1.40 (0.74–2.64).
Poor sleep quality (difficulty maintaining sleep) and acute coronary
events in men: aHR 1.12 (0.84–1.48).
Poor sleep qualtiy (difficulty maintaining sleep) and acute coronary
events in women: aHR 1.53 (0.99–2.37).
Mesas, 201064 6.8 y All-cause mortality: 897/3820 Sleep duration and all-cause mortality: <5 h: aOR 1.42 (1.04–1.96),
6 h: aOR 1.23 (0.90–1.69), 7 h: aOR 1.00, 8 h: aOR 1.34 (1.02–
1.76), 9 h: aOR 1.48 (1.12–1.96), 10 h: aOR 1.73 (1.30–2.29),
>11 h: aOR 1.66 (1.23–2.24).
Pan, 201465 Up to 8 y Stroke mortality: 1381/63 257 Sleep duration and stroke deaths: <5 h: aHR 1.25 (1.05–1.50), 6 h:
aHR 1.01 (0.87–1.18), 7 h: aHR 1.00, 8 h: aHR 1.09 (0.95–1.26),
>9 h: aHR 1.54 (1.28–1.85).
Sleep duration and ischaemic or unspecified stroke deaths: <5 h:
aHR 1.37 (1.12–1.68), 6 h: aHR 1.04 (0.87–1.24), 7 h: aHR 1.00,
8 h: aHR 1.14 (0.96–1.34), >9 h: aHR 1.68 (1.36–2.06).
Sleep duration and hemorrhagic stroke death: <5 h: aHR 0.92 (0.62–
1.36), 6 h: aHR 0.91 (0.67–1.24), 7 h: aHR 1.00, 8 h: aHR 0.97
(0.73–1.29), >9 h: aHR 1.14 (0.76–1.72).
Patel 200466 14 y All-cause mortality: 5409/82 969.
CVD mortality: 1084/82 969
Sleep duration and all-cause mortality: <5 h: aRR 1.08 (0.96–1.22),
6 h: aRR 0.99 (0.92–1.06), 7 h: aRR 1.00, 8 h: aRR 1.11 (1.03–
1.19), >9 h: aRR 1.40 (1.25–1.55). Sleep duration and
cardiovascular mortality: <5 h: aRR 1.04 (0.79–1.35), 6 h: aRR
Continued
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Table 3. Continued
Study ID Follow-up Duration Outcomes and Crude Rate of Outcomes Results
1.06 (0.91–1.25), 7 h: aRR 1.00, 8 h: aRR 1.12 (0.95–1.31), >9 h:
aRR 1.56 (1.25–1.96).
Pollak, 199067 3.5 y All-cause mortality: 309/1855 Incremental increase in h of sleep and all-cause mortality in men: HR
0.96 (0.66–1.39).
Incremental increase in h of sleep and all-cause mortality in women:
HR 1.11 (0.80–1.54).
Qiu, 201168 3 y All-cause mortality: 5199/12 671 Sleep duration and all-cause mortality: <5 h: aHR 0.97 (0.88–1.08),
6 h: aHR 1.05 (0.95–1.16), 7 h: aHR 1.00 (0.90–1.11), 9 h: aHR
0.95 (0.83–1.07), >10 h: aHR 1.09 (1.00–1.18).
Sleep duration and all-cause mortality and men: <5 h: aHR 1.17
(1.01–1.38), 6 h: aHR 1.06 (0.91–1.25), 7 h: aHR 1.17 (0.99–
1.37), 9 h: aHR 1.08 (0.89–1.31), >10 h: aHR 1.22 (1.08–1.38).
Sleep duration and all-cause mortality and women: <5 h: aHR 0.85
(0.75–0.98), 6 h: aHR 1.02 (0.90–1.15), 7 h: aHR 0.88 (0.76–
1.01), 9 h: aHR 0.86 (0.72–1.02), >10 h: aHR 1.00 (0.90–1.11).
Sleep quality (poor vs good) and all-cause mortality: aHR 0.91 (0.83–
1.00).
Sleep quality (poor vs good) and all-cause mortality in men: aHR 1.11
(0.95–1.30).
Sleep quality (poor vs good) and all-cause mortality in women: aHR
0.81 (0.71–0.91).
Qureshi, 199769 10 y Stroke 322/7844. CHD: 474/7844 Sleep duration and risk for stroke: <6 h: aOR 1.0 (0.7–1.5), 6 to 8 h:
aOR 1.0, >8 h: aOR 1.5 (1.1–2.0).
Sleep duration and CHD: <6 h: aOR 1.3 (1.0–1.8), 6 to 8 h: aOR 1.0,
>8 h: aOR 1.1 (0.8–1.5).
Rhee, 201270 Up to 15 y All-cause mortality: 990/14 533 Sleep duration and all-cause mortality: ≤5 h: aHR 1.53 (1.11–2.12),
6 to 7 h: aHR 1.04 (0.88–1.22), ≥8 h: aHR 1.00.
Rod, 201471 22 y. All-cause mortality: 804/9098. CVD
mortality: 221/9098
Sleep duration and all-cause mortality in men: ≤5 h: aHR 1.11 (0.73–
1.68), 6 h: aHR 1.23 (1.01–1.50), 7 h: aHR 1.00, 8 h: aHR 1.18
(0.92–1.50), >9 h: aHR 1.44 (0.59–3.50).
Sleep duration and all-cause mortality in women: ≤5 h: aHR 1.21
(0.76–1.91), 6 h: aHR 1.14 (0.86–1.52), 7 h: aHR 1.00, 8 h: aHR
0.91 (0.63–1.30), >9 h: aHR 1.48 (0.60–3.65).
Sleep duration and CVD mortality: ≤6 h: aHR 1.18 (0.87–1.63), 7 to
8 h: aHR 1.00, >9 h: aHR 1.61 (0.40–6.59).
Poor sleep quality (disturbed sleep) and all-cause mortality in men:
aHR 0.85 (0.62–1.16).
Poor sleep quality (disturbed sleep) and all-cause mortality in women:
aHR 1.03 (0.70–1.52).
Poor sleep quality (disturbed sleep) and CVD mortality: aHR 1.04
(0.72–1.49).
Ruigomez, 199572 55.7 months All-cause mortality 224/1219 Sleep duration and all-cause mortality: <7 h: aRR 0.83 (0.56–1.23),
7 to 9 h: aRR 1.00, >9 h: aRR 1.37 (0.89–2.11).
Sleep duration and all-cause mortality in men: <7 h: aRR 1.06 (0.61–
1.83), 7 to 9 h: aRR 1.00, >9 h: 1.30 (0.71–2.38).
Sleep duration and all-cause mortality in women: <7 h: aRR 0.66
(0.37–1.16), 7 to 9 h: aRR 1.00, >9 h: 1.46 (0.79–2.70).
Ruiter Petrov, 201473 2 y Stroke (at least 1 symptom): 224/
5666
Sleep duration on stroke symptoms: <6 h: aHR 1.47 (0.89–2.45),
6 h: aHR 1.22 (0.82–1.81), 7 h: aHR 1.00, 8 h: aHR 1.30 (0.92–
1.83), ≥9 h: aHR 1.42 (0.82–2.45).
Sands-Lincoln, 201374 10.3 y CVD events: 7257/86 329 Sleep duration and CVD: ≤5 h: aHR 1.06 (0.96–1.16), 6 h: aHR 1.00
(0.95–1.06), 7 to 8 h: aHR 1.00, 9 h: aHR 0.95 (0.83–1.08), ≥10 h:
aHR 1.23 (0.89–1.70).
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Table 3. Continued
Study ID Follow-up Duration Outcomes and Crude Rate of Outcomes Results
Sleep duration and CHD: ≤5 h: aHR 1.08 (0.96–1.20), 6 h: aHR 1.00
(0.94–1.07), 7 to 8 h: aHR 1.00, 9 h: aHR 0.93 (0.80–1.08), ≥10 h:
aHR 1.33 (0.94–1.88).
Shankar, 200875 13 y CHD mortality: 1416/58 044 Sleep duration and CHD mortality: ≤5 h: aRR 1.57 (1.32–1.88), 6 h:
aRR 1.13 (0.98–1.31), 7 h: aRR 1.00, 8 h: aRR 1.12 (0.97–1.29),
≥9 h: aRR 1.79 (1.48–2.17).
Song, 201676 7.9 y Stroke: 3135/95 023 Sleep duration and stroke: <6 h: aHR 0.92 (0.81–1.05), 6 to 8 h: aHR
1.00, >8 h: aHR 1.29 (1.01–1.64).
Sleep duration and stroke in men: <6 h: aHR 0.90 (0.78–1.03), 6 to
8 h: aHR 1.00, >8 h: aHR 1.24 (0.96–1.60).
Sleep duration and stroke in women: <6 h: aHR 1.09 (0.75–1.60), 6
to 8 h: aHR 1.00, >8 h: aHR 1.91 (0.98–3.74).
Stone, 200977 Up to 4.1 y All-cause mortality: 793/6107 Sleep duration and all-cause mortality in men: <5 h: RH 1.2 (0.8–
1.8), 7 to 8 h: RH 1.00.
Sleep duration and all-cause mortality in women: <5 h: RH 1.8 (1.3–
2.5), 7 to 8 h: RH 1.00.
Strand, 201678 9.7 y CHD mortality: 711/392 164 Sleep duration and CHD mortality: <4 h: aHR 1.36 (0.88–2.10), 4 to
6 h: aHR 1.03 (0.85–1.24), 6 to 8 h: aHR 1.00, <8 h: aHR 1.28
(1.05–1.56).
Sleep duration and CHD mortality in men: <4 h: aHR 1.03 (0.53–
2.00), 4 to 6 h: aHR 1.06 (0.85–1.32), 6 to 8 h: aHR 1.00, <8 h:
aHR 1.11 (0.88–1.41).
Sleep duration and CHD mortality in women: <4 h: aHR 1.84 (1.03–
3.29), 4 to 6 h: aHR 0.99 (0.72–1.37), 6 to 8 h: aHR 1.00, <8 h:
aHR 1.81 (1.28–2.56).
Difficulty getting to sleep and CHD mortality: aHR 1.01 (0.80–1.26).
Suzuki, 200911 6 y All-cause mortality: 1004/14 001.
CVD mortality: 310/14 001
Sleep duration and all-cause mortality: ≤5 h: aHR 0.92 (0.66–1.28),
6 h: aHR 1.06 (0.80–1.39), 7 h: aHR 1.00, 8 h: aHR1.36 (1.09–
1.70), 9 h: aHR 1.41 (1.05–1.90), ≥10 h: aHR 1.96 (1.49–2.57).
Sleep duration and all-cause mortality in men: ≤5 h: aHR 1.08 (0.72–
1.61), 6 h: aHR 1.05 (0.75–1.47), 7 h: aHR 1.00, 8 h: aHR 1.36
(1.04–1.78), 9 h: aHR 1.52 (1.08–2.15), ≥10 h: aHR 1.86 (1.34–
2.56).
Sleep duration and all-cause mortality in women: ≤5 h: aHR 0.71
(0.39–1.29), 6 h: aHR 1.08 (0.67–1.74), 7 h: aHR 1.00, 8 h: aHR
1.39 (0.92–2.09), 9 h: aHR 1.15 (0.64–2.09), ≥10 h: aHR 2.27
(1.37–3.76).
Sleep duration and CVD mortality: ≤5 h: aHR 1.10 (0.62–1.93), 6 h:
aHR 0.85 (0.50–1.45), 7 h: aHR 1.00, 8 h: aHR 1.52 (1.01–2.29).
9 h: aHR 1.55 (0.91–2.63), ≥10 h: aHR 1.95 (1.18–3.21).
Sleep duration and CVD mortality in men: ≤5 h: aHR 0.97 (0.46–
2.05), 6 h: aHR 0.75 (0.38–1.48), 7 h: aHR 1.00, 8 h: aHR 1.05
(0.63–1.75). 9 h: aHR 1.26 (0.65–2.45), ≥10 h: aHR 1.71 (0.94–
3.11).
Sleep duration and CVD mortality in women: ≤5 h: aHR 1.48 (0.59–
3.67), 6 h: aHR 1.08 (0.44–2.66), 7 h: aHR 1.00, 8 h: aHR 2.83
(1.39–5.76). 9 h: aHR 2.32 (0.93–5.77), ≥10 h: aHR 2.31 (0.91–
5.82).
Poor sleep quality (frequent awakening) and all-cause mortality: aHR
0.99 (0.83–1.18).
Poor sleep quality (frequent awakening) and all-cause mortality in
men: aHR 1.00 (0.81–1.24).
Poor sleep quality (frequent awakening) and all-cause mortality in
women: aHR 0.96 (0.69–1.31).
Poor sleep quality (frequent awakening) and CVD mortality: aHR 0.91
(0.66–1.26).
Continued
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Table 3. Continued
Study ID Follow-up Duration Outcomes and Crude Rate of Outcomes Results
Poor sleep quality (frequent awakening) and CVD mortality in men:
aHR 0.97 (0.64–1.48).
Poor sleep quality (frequent awakening) and CVD mortality in women:
aHR 0.81 (0.49–1.35).
Tamakoshi, 200479 9.9 y All-cause mortality: 11 071/
104 010
Sleep duration and all-cause mortality in men: ≤4 h: aRR 0.88 (0.44–
1.78), 5 h: aRR 1.07 (0.83–1.38), 6 h: aRR 1.11 (0.95–1.28), 7 h:
aRR 1.00, 8 h: aRR 1.19 (1.07–1.32), 9 h: aRR 1.27 (1.08–1.48),
≥10 h: aRR 1.75 (1.46–2.09).
Sleep duration and all-cause mortality in women: ≤4 h: aRR 1.83
(1.20–2.81), 5 h: aRR 1.18 (0.90–1.53), 6 h: aRR 1.17 (0.99–1.39),
7 h: aRR 1.00, 8 h: aRR 1.35 (1.17–1.56), 9 h: aRR 1.57 (1.26–
1.96), ≥10 h: aRR 2.12 (1.67–2.68).
Tsubono 199380 4 y All-cause mortality: 207/4318 Sleep duration and all-cause mortality: ≤6 h: aRR 1.26 (0.81–1.97),
7 to 8 h: aRR 1.00, ≥9 h: aRR 1.58 (1.16–2.15).
Tu, 201281 4 y Unclear Sleep duration and CHD in women: ≤4 h: aOR 1.46 (1.26–1.70), 5
h: aOR 1.28 (1.15–1.43), 6 h: aOR 1.11 (1.02–1.21), 7 h: aOR 1.00,
8 h: aOR 0.95 (0.86–1.03), 9 h: aOR 1.07 (0.92–1.25), ≥10 h: aOR
1.41 (1.19–1.67).
Sleep duration and stroke in women: ≤4 h: aOR 1.75 (1.49–2.07),
5 h: aOR 1.37 (1.21–1.55), 6 h: aOR 1.16 (1.05–1.29), 7 h: aOR
1.00, 8 h: aOR 1.05 (0.94–1.17), 9 h: aOR 1.07 (0.89–1.29), ≥10 h:
aOR 1.88 (1.56–2.27).
Twig, 201682 6.4 y Coronary artery disease 92/26 023 Poor sleep quality (highest vs lowest quartile) and coronary artery
disease: aHR 2.38 (1.37–4.11).
Von Ruesten, 201283 8 y Stroke 169/23 620. MI 197/23 620 Sleep duration and MI: <6 h: aHR 1.44 (0.85–2.43) 6 h: aHR 0.80
(0.53–1.20), 7 h: aHR 1.00, 8 h: aHR 0.82 (0.56–1.19), ≥9 h: aHR
0.89 (0.54–1.49).
Sleep duration and strokes: <6 h: aHR 2.06 (1.18–3.59), 6 h: aHR
1.13 (0.72–1.77), 7 h: aHR 1.00, 8 h: aHR 1.16 (0.77–1.73), ≥9 h:
aHR 1.65 (1.00–2.73).
Wang, 201684 3.98 y MI: 423/101 510. All-cause
mortality: 1793/101 510
Sleep duration and MI: ≤5 h: aHR 0.89 (0.60–1.30), 6 h: aHR 0.84
(0.61–1.16), 7 h: aHR 1.00, 8 h: aHR 0.86 (0.66–1.13), ≥9 h: aHR
1.12 (0.58–2.16).
Sleep duration and all-cause mortality: ≤5 h: aHR 1.23 (1.03–1.80),
6 h: aHR 1.95 (0.81–1.12), 7 h: aHR 1.00, 8 h: aHR 1.06 (0.92–
1.20), ≥9 h: aHR 1.65 (1.22–2.22).
Werle, 201185 9 y All-cause mortality: 141/187. CV
mortality: 56/187
Incremental increase in h of sleep and all-cause mortality: aHR 0.95
(0.89–1.02).
Incremental increase in h of sleep and cardiovascular mortality: aHR
0.83 (0.73–0.95).
Westerlund 20138 13 y CVD mortality: 857/41 192. Stroke:
1685/41 192. MI: 1908/41 192
Sleep duration and CVD mortality: ≤5 h: aHR 1.11 (0.76–1.64), 6 h:
aHR 1.17 (0.88–1.55), 7 h: aHR 1.00, ≥8 h: aHR 1.12 (0.85–1.47).
Sleep duration and CVD: ≤5 h: aHR 1.05 (0.88–1.26), 6 h: aHR
0.97 (0.86–1.09), 7 h: aHR 1.00, ≥8 h: aHR 1.00 (0.89–1.13).
Sleep duration and stroke: ≤5 h: aHR 1.05 (0.80–1.37), 6 h: aHR
0.95 (0.79–1.14), 7 h: aHR 1.00, ≥8 h: aHR 0.87 (0.72–1.04).
Sleep duration and MI: ≤5 h: aHR 1.19 (0.92–1.55), 6 h: aHR 1.05
(0.88–1.25), 7 h: aHR 1.00, ≥8 h: aHR 1.19 (1.00–1.41).
Poor sleep quality (difficulty maintaining sleep) and CVD mortality:
mostly/always aHR 0.97 (0.77–1.20).
Wingard, 198386 9 y All-cause mortality: 369/6928 Sleep duration and all-cause mortality in men: ≤6 h: 52/352, 7 to
8 h: 142/1735, ≥9 h: 15/132.
Sleep duration and all-cause mortality in women: ≤6 h: 35/386, 7 to
8 h: 107/1902, ≥9 h: 17/200.
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steeper for long sleep duration compared with short
duration, so individuals with excessive sleeping patterns
may warrant further clinical assessment. Third, we provide
updated evidence that supports the J-shaped relationship
where longer sleep is associated with signiﬁcantly higher
mortality and CVD and further the knowledge by highlight-
ing that excess sleep is possibly associated with a greater
likelihood of harm than less sleep with spline analysis. In
addition, we found that sleep quality emerged as an
important risk factor for CHD, so clinicians should consider
nonrestorative sleep (or “waking up unrefreshed”) during
patient assessment. Finally, our study highlights current
evidence that sleep may be an important factor for
individuals who wish to adopt a healthier lifestyle—our
ﬁndings support public health campaigns promoting good
sleep practices and behaviors and the importance of the
clinician discussing sleep in primary care consultations.
St-Onge et al recently published a scientiﬁc statement on
behalf of the American Heart Association.91 Their review
surveyed the literature and found that sleep duration, mostly
short sleep, and sleep disorders are related to adverse
cardiometabolic risk, such as obesity, hypertension, type 2
diabetes mellitus, and CVD. Unlike their review, we focused
on mortality and CVD and quantitatively pooled the impact of
individual hours of sleep duration and these events. We were
able to show, with metaregression, that the association of
short sleep duration and adverse events was lost, but the
association of long sleep duration and adverse events still
persists. It is possible that the adverse outcomes associated
with short sleep duration may be manifested through the risk
factors described by St-Onge’s review. Our ﬁndings support
the clinical recommendations of the American Heart Associ-
ation, in which sleep behaviors should be addressed to
promote cardiac health, and public health campaigns address-
ing sleep behavior should include explicit guidelines for
adequate sleep.
Our meta-analysis results show a possible increase in
mortality with both long and short duration of sleep relative to
7 or 8 hours, but after spline analysis, there is no difference in
mortality for patients with shorter sleep duration. The spline
regression is the gold standard for metaregression for
nonlinear relationships to model exposures and outcomes.
We further used this method to perform analysis on the
subgroups studies that had more-complete reporting that
include crude event rates.
The exact mechanisms that underlie the association
between sleep and CVD and mortality are not fully under-
stood. Short sleep duration has been shown to increase levels
of leptin and ghrelin,92,93 which leads to increased appetite,
caloric intake, reduce energy expenditure, and facilitates the
development of obesity80 and impaired glycemic control.94
Cortisol also increases with reduced sleep, and altered growth
hormone metabolism may increase CVR.95 Low-grade inﬂam-
mation occurs with reduced sleep, which may be associated
with CVD and cancer. Long sleep duration may be associated
with an increased risk of CVD because of an adverse CVR
factor proﬁle or prevalent comorbidities that lead to fatigue,
such as chronic inﬂammatory disorders and anemia. Depres-
sive symptoms, low socioeconomic status, unemployment,
and low physical activity are also associated with long sleep
duration, which may confound the association of long sleep
with morbidity and mortality.20
Table 3. Continued
Study ID Follow-up Duration Outcomes and Crude Rate of Outcomes Results
Xiao, 201487 14 y All-cause mortality: 44 100/
239 896. CVD mortality: 11 635/
239 896
Sleep duration and all-cause mortality: <5 h: aRR 1.16 (1.11–1.26),
5 to 6 h: aRR 1.04 (1.02–1.06), 7 to 8 h: aRR 1.00, ≥9 h: aRR 1.11
(1.06–1.19).
Sleep duration and CVD mortality: <5 h: aRR 1.25 (1.13–1.38), 5 to
6 h: aRR 1.06 (1.02–1.10), 7 to 8 h: aRR 1.00, ≥9 h: aRR 1.07
(0.97–1.17).
Yeo, 201388 9 y All-cause mortality: 1580/13 164.
CVD mortality: 363/13 164
Sleep duration and all-cause mortality: ≤5 h: aHR 1.21 (1.03–1.41),
6 h: aHR 1.10 (0.95–1.27), 7 h: aHR 1.00, 8 h: aHR 1.03 (0.89–
1.19), 9 h: aHR 1.36 (1.11–1.67), ≥10 h: aHR 1.36 (1.07–1.72).
Sleep duration on CVD mortality: ≤5 h: aHR 1.40 (1.02–1.93), 6 h:
aHR 1.25 (0.92–1.69), 7 h: aHR 1.00, 8 h: aHR 1.04 (0.76–1.42),
9 h: aHR 1.26 (0.81–1.96), ≥10 h: aHR 1.37 (0.82–2.29).
Zawisza, 201589 10.8 y All-cause mortality 2093/2449. Incremental increase in h of sleep and all-cause mortality: aHR 1.04
(1.003–1.075).
Zuubier, 201590 7.3 y All-cause mortality: 154/1734. Sleep duration and all-cause mortality: <6 h: aHR 1.12 (0.77–1.65),
6 to 7.5 h: aHR 1.00, ≥7.5 h: 1.18 (0.70–1.98).
aHR indicates adjusted hazard ratio; aOR, adjusted odds ratio; aRR, adjusted risk ratio; CHD, coronary heart disease; CVD, cardiovascular disease; HR, hazard ratio; MI, myocardial
infarction; PSQI, Pittsburgh Sleep Quality Index; RH, relative hazard.
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An important consideration in the temporal relationship
between sleep and adverse outcomes is the potential
inﬂuence of CVR factors. For example, a Japanese study
observed that sleep disturbances were associated with a
higher risk of later-onset of type 2 diabetes mellitus.96 In
addition, it is unclear whether abnormal sleep is a marker of
Figure 2. Sleep duration and risk of all-cause mortality with linear and cubic splines. A, Linear splines
model (30 studies). B, DerSimonian–Laird random-effects meta-analysis models. CI indicates conﬁdence
interval.
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undiagnosed prevalent CVDs or of early/latent disease that
subsequently manifests in adverse cardiovascular outcomes
and death. Some studies have attempted to reduce the
effect of baseline prevalent CVD by excluding patients with
these conditions whereas other studies adjusted for these
factors. Despite our sensitivity analysis considering exclusion
Figure 3. Linear models for adverse cardiovascular events. A, CHD mortality (8 studies). B, CHD (14 studies). C, Stroke mortality (4 studies).
D, Stroke (15 studies). E, CVD mortality (11 studies). F, CVD (8 studies). CHD indicates coronary heart disease; CVD, cardiovascular disease.
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and adjustments, there may still be residual confounding
given that there may be undiagnosed or latent disease or
risk factors because some of these population-based studies
do investigate patients at baseline for these variables and
rely on self-reporting. The other important consideration is
whether the increased incident CVR is causally related to
sleep directly or whether abnormal sleep patterns may
contribute to adverse health behaviors that increase CVR
thereby contributing to the increase in cardiovascular
events.
Several studies have evaluated the mismatch between self-
reported sleep and more-objective measures. An analysis of
669 participants in the CARDIA (Coronary Artery Risk
Development in Young Adults) Sleep Study suggests a
moderate correlation between self-reported and objectively
measured sleep duration with evidence of systematic errors in
the mean and calibration.97 Another study of 2086 Hispanic
Americans suggests a moderate correlation between self-
reported sleep and actigraphy results.98 A smaller study that
compared self-reported sleep and actigraphy in 56 participants
reported a poor agreement between sleep duration and quality,
as assessed by a questionnaire and objectively measured
sleep.99 In addition, a different analysis of 63 patients who
were overweight and obese individuals and who underwent
actigraphy also reported a weak correlation between usual
sleep time and actigraph estimates.100 With respect to CVR,
studies suggest that self-reported sleep duration is different
from objectively assess sleep duration.101,102 Although the
exact reasons for discrepancies between subjective and
objective measures are not clear, it appears that self-reported
sleep is only, at best, moderately correlated with objective
measures of sleep and perhaps multiple measures of sleep
duration should be recommended for future studies.
In the current analysis, the study by Kripke et al53
represented more than one third of the entire cohort, and this
large study has implications to the interpretation of the results.
This cohort was a diverse group of adults who were friends or
relatives of American of Cancer Society volunteers who were
aged between 30 and 102 years. The mean age in this study
was 57 years and 43% of participants were female, which were
both slightly lower than the average of 60 years of age and 52%
female in all the included studies. In addition, the study took
place in the 1980s, which may affect the applicability of its
ﬁndings to the current population. Collectively, these ﬁndings
may limit the generalizability of the current study.
Our study has a number of limitations. Although we used
adjusted estimates where available, there are likely to be
residual or unmeasured confounding and bias. For example,
an underlying physical or mental health condition may be the
driver behind extreme sleep patterns. A key limitation was
that sleep duration was assessed by self-reported question-
naires. It is unclear whether this is truly reﬂective of actual
sleep patterns given that there are studies that clearly show
that with respect to CVR, self-reported sleep duration and
objectively assessed sleep duration are signiﬁcantly
different.101,102 Another limitation was the absence of
individual patient-level data, so we could not make assump-
tions about the CVR factor proﬁles of patients based on
their sleep duration or quality. Some studies did report
baseline risk factors for patients, but every study reported
different risk factors, and the combinations of the risk-factor
proﬁles reported were too heterogeneous to make general
assumptions. Although we demonstrated an association
between sleep quality, duration, and outcomes, these rela-
tionships cannot infer causality and it is unclear whether sleep
duration or quality is a marker of prevalent CVR, an adverse
CVR factor proﬁle, or adverse health behaviors that contribute
to the adverse outcomes reported.
Conclusion
In conclusion, we found a signiﬁcant association between
deviations in sleep duration and both mortality and adverse
cardiovascular outcomes. National guidelines should consider
advocating this as the recommended sleep duration. We also
found evidence that sleep duration above the recommended
level of 7 to 8 hours was associated with a moderate degree
of harm compared with sleeping less than the suggested
duration. Furthermore, the greater the divergence from the
recommended durations of sleep, the greater the association
for cardiovascular harm and mortality. Our study suggests
that abnormal sleep is a marker of elevated CVR—and greater
consideration should be given in exploring during patient
consultations in both the duration and quality of sleep.
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